NCT03945604View on ClinicalTrials.gov

A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

June 4, 2019

Primary Completion Date

February 9, 2021

Study Completion Date

February 9, 2021

Conditions
Triple Negative Breast Cancer
Interventions
DRUG

SHR-1210 + Apatinib +Fluzoparib

SHR-1210 will be administered as an intravenous infusion Apatinib tablets will be given orally Fluzoparib capsule will be given orally 28 days per cycle, until disease progression or unacceptable toxicity.

Trial Locations (1)

100142

Beijing Cancer Hosptial, Beijing

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT03945604 - A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC | Biotech Hunter | Biotech Hunter